Israeli medical imaging firm Elbit Medical Imaging may be on the acquisition warpath soon. The Haifa company is weighing its options for spending the windfall it received from GE Medical Systems of Milwaukee, which purchased Elbit's Diasonics Vingmed
Israeli medical imaging firm Elbit Medical Imaging may be on the acquisition warpath soon. The Haifa company is weighing its options for spending the windfall it received from GE Medical Systems of Milwaukee, which purchased Elbit's Diasonics Vingmed Ultrasound subsidiary for $228 million in April (SCAN 4/29/98). Elbit executives say their company is defining its strategic direction in healthcare and is investigating various technologies and activities that would complement its medical imaging operations.
Elbit recorded a one-time net profit for its first quarter of $91.2 million on the sale, and returned some of the money to its shareholders in the form of a $1 a share one-time dividend that was paid on June 30. There are about 21.5 million shares of Elbit stock outstanding, leaving Elbit with a substantial sum of money to put to use.
Elbit also released financial results for its second quarter (end-June) indicating that the company posted revenues of $83.1 million, up 5% compared with $79.2 million in the same period the year before. Elbit's Elscint subsidiary contributed $81.7 million in sales in the most recent quarter, with the rest coming from the company's Elbit Medical Services imaging services business. Elscint had revenues of $77.1 million in the second quarter of 1997. Elbit recorded net income of $3.1 million for the period, compared with $2.5 million in the second quarter of 1997.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.